Advanced Solid Tumors
Clinical research in locally advanced and metastatic solid tumor malignancies, including a broad range of cancer types across multiple active sites in Europe and beyond.
- Advanced or metastatic solid tumors
- Platinum-resistant ovarian cancer
- Second-line or later cervical cancer
- Second-line or later HER2-positive breast cancer
The sponsor’s oncology portfolio includes disease settings where treatment resistance and later-line management are central clinical concerns.
Melanoma and Skin Cancer
Research activity includes melanoma in both neoadjuvant and post-immunotherapy settings, reflecting interest in earlier intervention and treatment after checkpoint inhibitor exposure.
- Post-anti-PD-1 melanoma
- Neoadjuvant melanoma
These studies focus on tumors with established immunotherapy use and ongoing need for additional therapeutic options.
Head and Neck Oncology
The sponsor is active in head and neck squamous cell carcinoma, particularly stage III-IVA resectable locoregionally advanced disease, where perioperative treatment strategies are clinically important.
- Locoregionally advanced head and neck squamous cell carcinoma
- Resectable stage III-IVA disease
This area reflects interest in disease control before surgery and in settings where local and systemic treatment decisions intersect.
Lung Cancer
Clinical research also includes non-small cell lung cancer and small cell lung cancer after prior anti-PD-L1 treatment, covering both major lung cancer subtypes in later treatment lines.
- Post-anti-PD-L1 non-small cell lung cancer
- Post-anti-PD-L1 small cell lung cancer
The therapeutic emphasis extends to malignancies where resistance following immunotherapy remains a key challenge.
Immuno-Oncology and Anticancer Combinations
The sponsor’s trials center on immuno-oncology approaches, including TLR7/8 agonist and IL-2 beta/gamma programs in combination with established anticancer therapies.
- Pembrolizumab-based combinations
- TransCon TLR7/8 agonist
- TransCon IL-2 beta/gamma
- Combination therapy with chemotherapy and HER2-directed agents
These research interests span immune activation, checkpoint inhibition, and combination strategies across advanced and neoadjuvant oncology settings.
